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Background: Hip fractures are a common and serious consequence of osteoporosis, and hip fracture patients are
at high risk for recurrence. Appropriate pharmacotherapy reduces this risk and is associated with reduced mortality
after hip fracture, but a care gap exists for fracture prevention in these patients. This evaluation determined rates of
osteoporosis treatment and bone mineral density (BMD) testing in hip fracture patients following discharge from a
rehabilitation unit.
Methods: A prospective cohort study of hip fracture patients aged ≥ 50 on an inpatient rehabilitation unit in 2008
and 2011. Patients were seen by a nurse specialist, and encouraged to see their family physician for further
assessment and treatment. Physicians were sent a letter indicating the need to follow up with their patient. Patients
were contacted following discharge from hospital to determine treatment rates.
Results: Of 310 eligible hip fracture patients admitted to the rehabilitation unit in the years studied, 207 patients were
reached post-discharge and provided data. Of patients who were not previously taking osteoporosis medication, 59%
of patients from the 2008 cohort, and 42% of patients from the 2011 cohort had osteoporosis treatment initiated by six
months following discharge. By 2 months following discharge, 46% of patients in the 2008 cohort had a new BMD
performed or scheduled, while this was true for 14% of patients from the 2011 cohort. 35% of patients in 2011 had not
seen their family physician by 2 months following discharge.
Conclusions: Rates for osteoporosis treatment and BMD testing were higher than those reported in the literature for
patients not enrolled in case manager programs. BMD testing declined from 2008 to 2011. Lower treatment rates may
be due to concerns regarding reports of possible association between bisphosphonate use and atypical fractures.
Improving rates of patient follow-up with family physicians will be important for increasing hip fracture treatment rates
after discharge.
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Hip fractures are a common and serious consequence of
osteoporosis. In 2007, the number of hospitalizations for
hip fracture in Canada exceeded 28 000 [1]. Hip frac-
tures are associated with significant morbidity and mor-
tality, as well as a high cost to the health care system.
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reproduction in any medium, provided the orhas been shown to be as high as 25% [2]. In addition, pa-
tients experience significant morbidity and loss of func-
tion after hip fracture, with an estimated 60% of patients
requiring assistance and 33% totally dependent or in a
long-term care facility a year later [3,4]. Canada spends
an estimated $1.9 billion yearly on the treatment of
osteoporotic fractures, which is expected to rise to $2.4
billion for hip fractures alone by the year 2041 [5]. Of all
incident fractures, hip fractures have been found to have
the highest excess, which are similar in relative magni-
tude to the cost of coronary heart disease and stroke [6].
Patients with hip fracture are at high risk for recurrent
fracture; and have been reported to be at 1.9-2.5 timesd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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on the location of the subsequent fracture [7]. Appro-
priate pharmacotherapy, however can substantially re-
duce the risk of fracture. The risk of vertebral fracture
can be reduced by 30-70% depending on the therapy
and level of adherence; the reduction in risk of non-
vertebral fractures varies by fracture site [7]. In ad-
dition, bisphosphonates have all been associated with
reduced mortality after hip fracture [8-11]. Current
Canadian osteoporosis clinical practice guidelines iden-
tify patients with prior hip fracture as high risk for
future fractures and recommend that these patients are
investigated with a bone mineral density (BMD) and
offered appropriate pharmacotherapy and lifestyle re-
commendations [8]. Alendronate, risedronate, zoledro-
nic acid, and denosumab are first-line therapies for the
prevention of hip, vertebral and non-vertebral fractures
in post-menopausal women, and alendronate, risedro-
nate and zoledronic acid and denosumab are first-line
therapies for the prevention of fractures in men [8].
Despite the availability and benefit of these therapies, a
care gap between recommendations and practice has
been identified in Canada for fracture prevention in pa-
tients who have had a fracture, with fewer than 20% of
women and 10% of men receiving pharmacotherapy to
prevent further fractures [12-14].
In 2006 an initiative known as ‘Fracture? Think
Osteoporosis’ (FTOP) was launched in Hamilton,
Ontario with the aim of reducing subsequent fractures
in patients presenting with fragility fractures, by impro-
ving recognition and treatment of osteoporosis in these
patients. As part of this program patients presenting
with fragility fracture were assessed in hospital and
followed after discharge by a clinical nurse specialist
acting as a case manager. Using an osteoporosis case
manager has previously been shown to be a cost-
effective way to substantially improve osteoporosis
treatment rates and the quality of osteoporosis care
after hip fracture during acute care hospitalization
compared to usual care or educational initiatives alone
[15-18]. Few programs, however, have focused on the
rehabilitation population.
The purpose of this study was to examine the rate of
appropriate post-fracture pharmacotherapy within six
months of discharge in hip fracture patients admitted
to rehabilitation during 2008 and 2011. A secondary
objective was to examine the number of patients who
had a BMD scheduled or performed and whether treat-
ment initiation was related to ordering a BMD.Methods
Design
This was a prospective cohort study.Patients
Patients aged 50 years or older who had a hip frac-
ture and were inpatients at the rehabilitation unit of a
tertiary-care hospital in Hamilton, Ontario in the years
2008 and 2011 were included in this study. This allowed
comparison over time of care provided to patients
involved in the FTOP program. Rehabilitation unit
admission criteria included medically stable patients
with clearly defined and attainable rehabilitation goals
understood and agreed upon by the patient, with an
estimated time to achieve goals ≤21 days, and able to
physically tolerate participation in an active treatment
program (1 hour + sitting tolerance twice daily; weight
bearing; initial tolerance for physical activity for ½ to
1 hour three times daily).
Description of the FTOP program
The FTOP program is a chronic disease management
program for osteoporosis and consequent fractures in
Hamilton. The objective of this multi-faceted interdiscip-
linary program is to improve diagnosis and treatment of
osteoporosis in patients with fragility fractures and to
decrease the rate of subsequent fractures in those indi-
viduals greater than 50 years who have experienced a frac-
ture. Fragility fracture was defined as fracture that occurs
spontaneously or following minor trauma such as a fall
from standing height or less [8]. FTOP is a Hamilton
Health Sciences initiative to reduce hip, spine and wrist
fractures. The program included education and academic
detailing by local osteoporosis leaders for rehabilitation
and geriatric teams with respect to osteoporosis diagnosis
and treatment in the immediate post-fracture period.
All hip fracture patients receive standardized orders
which include calcium carbonate 500 mg and vitamin D
2000 IU daily in the inpatient hospital setting on acute
care orthopedic units. Then, patients are transferred to
the rehabilitation unit following their acute phase of care.
Fragility hip fracture patients are assessed by the clinical
nurse specialist on the rehabilitation ward. The clinical
nurse specialist provides education to the patient regar-
ding osteoporosis, falls, and appropriate nutritional and
supplement intake. The patient is also given a “fracture
alert” form (see Additional file 1), that indicates that they
should follow up with their family physician for further
assessment, including bone mineral density (BMD) testing
and consideration of treatment for osteoporosis. A letter
(see Additional file 2) is also sent to the patient’s family
physician suggesting that they follow up with their patient
following discharge from hospital for further assessment
and treatment for osteoporosis.
Two months after discharge from hospital, hip fracture
patients receive a phone call from the clinical nurse spe-
cialist to determine if they have had a BMD and if they
are now on treatment for osteoporosis. At that time,
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and treatment, and if necessary, the need to follow up
with their family physician. If patients are not on treat-
ment for osteoporosis at the 2-month follow up, they are
given a further follow up call six months after discharge.
Only one clinical nurse specialist was involved in the
study and provided the patient assessments, education
and follow-up, and sent out fracture alert letters to phy-
sicians for both the 2008 and 2011 patient cohorts.
Patients with fractures secondary to malignancy were
excluded. Patients were also excluded if they were trans-
ferred to an outside facility for care.
Data collection
Data obtained included: age, gender, fracture type/location,
diagnosis of osteoporosis on chart, knowledge of osteo-
porosis diagnosis, if taking calcium supplement and dose,
amount of dietary calcium, if taking vitamin D supplement
and dose, if taking osteoporosis medication and if using
appropriately as assessed by nurse, osteoporosis medi-
cations started in hospital, seen family doctor since dis-
charge, BMD prior to admission, BMD completed or
scheduled since discharge, falls and fracture (and fracture
type/location) since discharge. A database containing de-
identified data was used for analysis. Care provided inclu-
ding treatment in-hospital was confirmed by the patient
chart and care initiated post-discharge was collected by
patient report.
Outcome variables
The primary outcome was initiation of osteoporosis treat-
ment (i.e. post-discharge) by 6-months. Medications con-
sidered were: any oral bisphosphonate, zoledronic acid,
teriparatide, denosumab.
The secondary outcome was a new BMD performed
or scheduled since discharge (patient self-report). Since
only patients who were not on treatment at 2-months
were contacted at 6-months, numbers are reported for
both the 2- and 6-month time periods.
Statistical analysis
Continuous variables were summarized using mean, stan-
dard deviation and categorical variables were summarized
as percentages. Between-group comparisons were per-
formed using Pearson chi-square and independent samples
t-tests.
Statistical significance was defined as p < 0.05. Statistical
analyses were performed with SPSS software 20.0® (SPSS
Inc., Chicago IL).
Ethical considerations
No formal consent process was used as data collected was
considered part of regular care. The study was approved
by the Hamilton Health Sciences Research Ethics Board.Results
A total of 821 hip fracture patients presented at the tea-
ching hospital in the two years studied (439 in the year
2008 and 382 in the year 2011). Of these patients, 316
(38%) were transferred to the rehabilitation unit. The
remaining patients were transferred to their community
hospital (n = 94), other rehabilitation hospital (n = 6),
chronic care hospital (n = 18), home care program (n = 83),
home for the aged or nursing home (n = 181), home
(n = 52), ambulatory out-patient clinic (n = 1), other un-
classified health institution (n = 4), or signed out (n = 2)
or died (n = 64). As described in Figure 1, of 316 hip
fracture patients transferred to rehabilitation, 310 had
fragility fractures and were eligible for study (153 from
the 2008 cohort, and 157 from the 2011 cohort). After
excluding patients unable to be reached for the 2-month
or 6-month follow-up calls, a total of 207 patients made
up the final analysis cohort.
The mean age of patients analyzed from 2008 and
2011 was 81.5 years, ranging from 52–104 years. There
were 150 females and 57 males. At the time of initial
assessment, 56% of patients from 2008 and 52% of
patients from 2011 had a diagnosis of osteoporosis docu-
mented in their chart (Table 1).
Calcium and vitamin D
By six months post-discharge from rehabilitation, 93%
(102/110) of patients from the 2008 cohort and 81%
(79/97) of patients from the 2011 cohort were taking
calcium supplementation (≥500 mg). 94% (103/100) and
93% (90/97) of patients were taking vitamin D supple-
mentation (≥800 IU) in 2008 and 2011, respectively.
Please refer to Table 2.
Initiation of pharmacotherapy
Overall 75% (82/110) of patients from the 2008 cohort
and 56% (54/97) of patients from the 2011 cohort were
taking osteoporosis medication 6 months after discharge
from rehabilitation (Table 2). Of patients who were not
previously taking osteoporosis medication, 59% (39/66)
of patients from the 2008 cohort and 42% (29/69) of
patients from the 2011 cohort had treatment initiated by
6 months after discharge from rehabilitation.
Bone mineral density testing
By 2 months post discharge from rehabilitation, 46%
(54/118) of patients in the 2008 cohort had a new BMD
performed or scheduled. Only 14% (15/108) of patients
in the 2011 cohort had a new BMD performed or sche-
duled by the 2-month follow-up. Of the patients who
were not on treatment at 2-months and could be con-
tacted again at 6-months (Figure 1; n = 46 for 2008 and
n = 49 for 2011), 61% (2008) and 20% (2011) had a new
BMD performed or scheduled.
Table 1 Baseline demographics and clinical characteristics, % (n)
2008 2011
All patients Analysis cohort All patients Analysis cohort
(n = 153) (n = 110) (n = 157) (n = 97)
Age in years, mean (SD) 80.8 (8.82) 80.7 (8.93) 82.1 (9.36) 82.3 (9.34)
Female 73% (112) 72% (79) 69% (109) 73% (71)
Previous diagnosis (patient self-report) 37% (56) 40% (44) 24% (38) 34% (33)
Diagnosis OP in chart 52% (79) 56% (61) 46% (72) 52% (50)
OP treatment prior to fracture 33% (50) 40% (44) 22% (35) 29% (28)
Recent BMD* prior to fracture 31% (48) 35% (38) 17% (27) 22% (21)
Vitamin D supplement use prior to fracture 53% (81) 60% (66) 58% (91) 67% (65)
Calcium supplement use prior to fracture 54% (82) 60% (66) 53% (83) 62% (60)
Patient has heard of OP 80% (122) 83% (91) 66% (103) 77% (75)
*For the 2008 cohort, this was in the past 1-year; for the 2011 cohort, the past 2-years.
OP = osteoporosis.
Figure 1 Flow diagram. OP = osteoporosis and LTC = long-term care.
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Table 2 Percent (n) of patients with osteoporosis
pharmacotherapy within 6-months of discharge
2008 2011
(n = 110) (n = 97)






Taking at baseline n = 44 N = 28
Discontinued treatment
after baseline
n = 1 n = 3
Taking vitamin D supplement







Taking at baseline n = 66 N = 65
Discontinued treatment
after baseline
n = 3 n = 2
Taking calcium supplement







Taking at baseline n = 66 60
Discontinued treatment
after baseline
n = 4 n = 6
aPatients were not previously taking osteoporosis medication. (OP = osteoporosis).
bFor patients who were not contacted at 6-months (because they taking
osteoporosis treatment at the 2-month assessment), the answer the provided
regarding supplementation at 2-month assessment was used.
cPatients not taking any vitamin D prior to FTOP.
dPatients not taking any calcium prior to FTOP.
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rehabilitation, no difference was found in the BMD status
of those who were taking osteoporosis medication com-
pared to those who were not. However, in the 2011 co-
hort, 23% of patients taking osteoporosis medication by
2 months post discharge had a new BMD ordered since
involvement in FTOP, compared to 7% of those not on
treatment (p = 0.015). In addition 44% of patients being
treated with osteoporosis medication by the 2-month post
discharge mark had a recent BMD done in the last
1–2 years, compared to only 23% of non-treated patients
(p = 0.024).
Falls and fractures during follow-up
From the 2008 cohort, 13% (15/118) of patients had
fallen at least once by 2 months post discharge from
rehabilitation, and there were 5 subsequent fractures
(4 hip fractures, and 1 shoulder fracture). From the 2011
cohort, 15% (16/108) of patients reported to have fallen
at least once by 2 months post discharge, with 2 sub-
sequent hip fractures.Discussion
This study of hip fracture patients in the rehabilitation
setting demonstrated that involvement in the FTOP case
manager and academic detailing program resulted in
higher osteoporosis treatment and BMD rates than those
reported in the literature for patients not involved in
similar types of case-manager led programs [12-14,19].
A systematic review of 37 studies on post-fracture osteo-
porosis diagnosis and treatment found osteoporosis
treatment rates ranging from 0.5% to 38%, but only six
studies reported treatment rates greater than 10% [19].
In our study of patients involved in FTOP, among pa-
tients with no previous osteoporosis treatment 50% had
osteoporosis treatment initiated by 6 months post dis-
charge. These rates are consistent with previous studies
of case manager osteoporosis programs [15,20,21]. For
example, a randomized controlled trial evaluating a case
manager osteoporosis program in acute care for hip
fracture patients demonstrated improved rates of osteo-
porosis treatment in patients involved in the program,
with treatment initiated in 51% of these patients [15].
Our study demonstrated that 60% of patients had a diag-
nosis of osteoporosis documented in their chart, which
is an improvement on previously reported rates of post-
fracture osteoporosis diagnosis of less than 30% [12]. A
history of prior fracture rate in our patients (46%) was
consistent with literature from other settings, highligh-
ting prior fracture as an important risk factor for future
fracture [12,13,15,20].
Interestingly, we found no improvement in osteopo-
rosis treatment rates and BMD referral in 2011 com-
pared to three years earlier. In fact, we observed a
decline in post-fracture BMD testing from 2008 to 2011,
which is a concern considering BMD testing has been
associated with treatment initiation [22,23]. A possible
explanation for this decline in BMD testing could be the
implementation of the 2010 clinical practice guidelines
for osteoporosis care in Canada. These guidelines rec-
ommend that individuals over the age of 50 who have
had a fragility fracture of the hip are automatically at
high risk of future fracture and should be offered phar-
macologic therapy, regardless of BMD [8]- although we
did not see the increase in treatment rates one would
expect if this guideline was being followed. In fact, data
from the 2011 cohort did show that those patients who
received a recent BMD or had a new BMD ordered since
involvement in FTOP were more likely to receive osteo-
porosis treatment.
Unlike some previously reported case manager pro-
grams, our program did not refer patients to a specialty
clinic, but rather relied on primary care physicians for
patient care. A study that surveyed 1000 Ontario family
physicians found that over 80% of physicians wanted to
be more informed about osteoporosis management, and
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of osteoporosis was not well known by most family phy-
sicians [24]. The FTOP program aimed to improve this by
sending out alert letters to the patients’ family physicians,
incorporating a reminder and educational information
about post- hip fracture osteoporosis management. Sys-
tematic review has previously found this strategy to be
effective in increasing BMD testing and osteoporosis
medication use [25]. However, patients can only benefit if
they are actually seen by their family physician; and our
study found that in the 2011 group, 33% of patients had
not seen their family physician by 6 months after dis-
charge from rehabilitation.
Standardized orders for calcium and vitamin D in
acute care for patients with fractures were in place at
the hospital for both 2008 and 2011 cohorts. The high
rates of calcium and vitamin D use in our patients in
hospital (92% and 96% respectively in the 2011 cohort)
would suggest these have been integrated into routine
clinical practice. In contrast, it is clear that the number
of patients being treated with other osteoporosis medica-
tion in hospital has declined, as 81% of patients did not
have osteoporosis treatment ordered in hospital in 2011.
In comparison, a previous study found that 56% of pa-
tients transferred to a rehabilitation or a geriatrics ward
between 2003 and 2004 were started on a bisphospho-
nate during index admission [20]. A possible contributor
to this decline in treatment initiation could be the emer-
gence of reports about atypical fractures associated with
bisphosphonate use, although this has since been shown
to have low incidence. One study demonstrated the risk
of proximal femur fractures with bisphosphonate the-
rapy to be 2.3 per 10 000 patient years [26].
Our results are consistent with the findings of a
systematic review of studies evaluating osteoporosis
diagnosis and/or treatment post-fracture, where the
proportion of patients diagnosed or treated for osteo-
porosis appeared to be greater in follow-up studies than
at discharge [12]. However, success has been reported
with a post-fracture osteoporosis education and treat-
ment program pre-discharge, with >95% of patients ap-
propriately diagnosed and treated, but to accomplish
this required the full cooperation of orthopaedic sur-
geons and residents, orthopaedic technologists, allied
health-care professionals and administrative staff in
addition to a dedicated coordinator [17].
There are limitations to this study that should be
acknowledged. The sample was limited by the number of
patients who were admitted into rehabilitation (n = 316),
and by the substantial number of patients with whom we
were unable to follow-up after discharge from rehabili-
tation (n = 103) for various reasons (Figure 1). Given the
small sample size, our analysis was limited to mainly
descriptive statistics. The results from this rehabilitationpopulation may not be applicable to other patient groups,
for example those in long term care or home care pro-
grams. The results post-discharge from rehabilitation are
based on patient self-report. In this elderly population, pa-
tients may be unfamiliar with the medication they take
and recall bias may be an issue for reported use of osteo-
porosis treatment as well as calcium and vitamin D. Ad-
herence is a known issue with osteoporosis medication;
research suggests that approximately 20-30% of osteopo-
rosis patients will stop taking their bisphosphonates,
raloxifene or HRT by 12 months after these medications
were prescribed [27]. Adherence was not measured in this
study, and patients treated at 2 months post-discharge
were assumed to be still on treatment at the six month
mark. We did not contact patients at 6-months if they
were taking treatment at the 2-month follow-up, thus our
analysis cohort was limited for examining BMD variables
at 6-months.
Conclusions
Future research should focus on better integration bet-
ween primary care physicians and hospitals to improve
osteoporosis treatment rates for hip fracture patients post-
discharge from rehabilitation. Ensuring that patients fol-
low-up with their family physicians has the potential to
impact mortality in hip fracture patients. The mean age of
patients in our sample was 82; many physicians have un-
certainties around applying treatment guidelines to older
patients with comorbidities and polypharmacy. There is a
need to educate both patients and health care profes-
sionals around treating older patients after hip fracture.
Our team is currently updating the 2010 Canadian Osteo-
porosis Guidelines with a focus to closing the care gap
and reducing the risk of future fracture in high risk popu-
lations such as elderly populations with hip fracture.
Additional files
Additional file 1: Fracture alert form.
Additional file 2: Fracture alert to general practitioner.
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